COLLEGIUM PHARMACEUTICAL, INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
COLLEGIUM PHARMACEUTICAL, INC.
By: /s/ Vikram Karnani
Vikram Karnani
Chief Executive Officer
| Signature | Title | Date |
|---|---|---|
| /s/ Vikram Karnani | President and Chief Executive Officer (Principal Executive Officer) and Director | February 26, 2026 |
| Vikram Karnani | ||
| /s/ Colleen Tupper | Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | February 26, 2026 |
| Colleen Tupper | ||
| /s/ Gino Santini | Chairman of the Board | February 26, 2026 |
| Gino Santini | ||
| /s/ Rita Balice-Gordon, Ph.D. | Director | February 26, 2026 |
| Rita Balice-Gordon, Ph.D. | ||
| /s/ Garen G. Bohlin | Director | February 26, 2026 |
| Garen G. Bohlin | ||
| /s/ John A. Fallon, M.D. | Director | February 26, 2026 |
| John A. Fallon, M.D. | ||
| /s/ John G. Freund, M.D. | Director | February 26, 2026 |
| John G. Freund, M.D. | ||
| /s/ Nancy Lurker | Director | February 26, 2026 |
| Nancy Lurker | ||
| /s/ Gwen Melincoff | Director | February 26, 2026 |
| Gwen Melincoff | ||
| /s/ Carlos Paya | Director | February 26, 2026 |
| Carlos Paya | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated.
Index to Consolidated Financial Statements
| Audited Consolidated Financial Statements | Pages |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID 34) | F-2 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Operations for the Years Ended December 31, 2025, 2024, and 2023 | F-5 |
| Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2025, 2024, and 2023 | F-6 |
| Consolidated Statements of Shareholders' Equity for the Years Ended December 31, 2025, 2024, and 2023 | F-7 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2025, 2024, and 2023 | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.